- Home
- CIO vs TLSI Comparison
CIO vs TLSI Comparison
Compare CIO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- TLSI
- Stock Information
- Founded
- CIO 2013
- TLSI 2010
- Country
- CIO Canada
- TLSI United States
- Employees
- CIO N/A
- TLSI N/A
- Industry
- CIO Real Estate Investment Trusts
- TLSI Medical Specialities
- Sector
- CIO Real Estate
- TLSI Health Care
- Exchange
- CIO Nasdaq
- TLSI Nasdaq
- Market Cap
- CIO 280.5M
- TLSI 244.3M
- IPO Year
- CIO 2014
- TLSI N/A
- Fundamental
- Price
- CIO $6.90
- TLSI $4.74
- Analyst Decision
- CIO Hold
- TLSI Strong Buy
- Analyst Count
- CIO 1
- TLSI 4
- Target Price
- CIO N/A
- TLSI $11.13
- AVG Volume (30 Days)
- CIO 390.6K
- TLSI 128.5K
- Earning Date
- CIO 11-06-2025
- TLSI 11-13-2025
- Dividend Yield
- CIO 5.80%
- TLSI N/A
- EPS Growth
- CIO N/A
- TLSI N/A
- EPS
- CIO N/A
- TLSI N/A
- Revenue
- CIO $168,892,000.00
- TLSI $35,990,000.00
- Revenue This Year
- CIO $0.32
- TLSI $56.71
- Revenue Next Year
- CIO $3.20
- TLSI $52.25
- P/E Ratio
- CIO N/A
- TLSI N/A
- Revenue Growth
- CIO N/A
- TLSI 45.50
- 52 Week Low
- CIO $4.19
- TLSI $3.42
- 52 Week High
- CIO $7.01
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- CIO 35.33
- TLSI 47.09
- Support Level
- CIO $6.87
- TLSI $4.57
- Resistance Level
- CIO $7.00
- TLSI $5.18
- Average True Range (ATR)
- CIO 0.02
- TLSI 0.23
- MACD
- CIO -0.01
- TLSI -0.02
- Stochastic Oscillator
- CIO 23.08
- TLSI 37.23
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.